Working… Menu

Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04977375
Recruitment Status : Not yet recruiting
First Posted : July 26, 2021
Last Update Posted : July 26, 2021
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Chirag G. Patil, Cedars-Sinai Medical Center

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2024